Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. scores highest on Torque (67) and lowest on Price (32). Its PosiPenta is 50.03 out of 100, around the middle of similar companies.
On the Penta Grid this week, Relmada Therapeutics, Inc. is Grid #283 of 837 in the Healthcare sector in United States, and Grid #1,867 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. | 50.03 | 32 | 56 | 42 | 67 | 54 |
| Mobia Medical, Inc. | 42.85 | 33 | 32 | 32 | 59 | 58 |
| Kyverna Therapeutics, Inc. | 30.87 | 28 | 22 | 26 | 38 | 41 |
| Capricor Therapeutics, Inc. | 38.82 | 33 | 39 | 27 | 36 | 60 |
| Galectin Therapeutics Inc. | 50.76 | 0 | 33 | 54 | 96 | 71 |
| CapsoVision, Inc. | 40.57 | 2 | 63 | 42 | 34 | 62 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.52 |
| P/B ratio | 1.60 |
EEarnings
| Trailing EPS | ₹-83.35 |
| Forward EPS | ₹-38.83 |
NNitro
| Price | 293.62 |
| 52-week high | 757.72 |
| 52-week low | 170.77 |
| Fall from 52-week high | 61.2% |
TTorque
| Return on equity (ROE) | -55.66% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 0.51 |
| Market cap | ₹3,132 Cr |
| Insider holding | 3.23% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Relmada Therapeutics, Inc.'s PosiPenta score?
Relmada Therapeutics, Inc.'s PosiPenta is 50.03 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Relmada Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Relmada Therapeutics, Inc. is Grid #283 of 837 in the Healthcare sector in United States, and Grid #1,867 of 4,000 in United States.
Which PosiPenta pillar is strongest for Relmada Therapeutics, Inc.?
Torque (durability), with a score of 67 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Relmada Therapeutics, Inc.?
Price (valuation), with a score of 32 out of 100: weaker than most similar companies.
Has Relmada Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.21 points, from 46.82 to 50.03.
PositoAI is for research and education only and is not investment advice.